Coumarin-based drugs: A patent review (2008 - present)

Expert Opinion on Therapeutic Patents

Volumn 22, Issue 4, 2012, Pages 437-454

  Kontogiorgis, Christos ^a   Detsi, Anastasia ^b   Hadjipavlou Litina, Dimitra ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b NATIONAL TECHNICAL UNIVERSITY OF ATHENS   (Greece)

Author keywords

antibacterial; anticancer; coumarin; NFAT signal inhibitors

Indexed keywords

ADENOSINE DIPHOSPHATE; CALANOLIDE A; CHOLINESTERASE INHIBITOR; COLUMBIANETIN; COUMARIN DERIVATIVE; DIHYDROXANTHYLETIN; FERULENOL; KU 32; MARMESIN; NOVOBIOCIN; UNCLASSIFIED DRUG; WARFARIN; WO 031709; WO 040153;

ALZHEIMER DISEASE; ANTIBACTERIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; BIOLOGY; CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; CYTOTOXICITY; DRUG SYNTHESIS; EX VIVO STUDY; HAIR GROWTH; HUMAN; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; KIDNEY POLYCYSTIC DISEASE; MICROWAVE IRRADIATION; MYCOBACTERIUM; NEURAL STEM CELL; NONHUMAN; PATENT; REVIEW; SKIN PIGMENTATION; STRUCTURE ACTIVITY RELATION; T LYMPHOCYTE; THROMBOCYTE AGGREGATION; TREATMENT OUTCOME;

ANIMALS; COUMARINS; DRUG DESIGN; HUMANS; MOLECULAR STRUCTURE; PATENTS AS TOPIC; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84859577362     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2012.678835     Document Type: Review

References (58)

1. Murray RDH, Mendez J, Brown RA. The Natural Coumarins. J. Wiley & Sons; New York: 1982
2. Murray RDH. Progress in the chemistry of organic natural products. In: Herz W, Kirby GW, Steglich W, Tamm C, editors. Coumarins. Volume 58 Springer-Verlag; New York: 1991. p. 84-316
3. Borges F, Roleira F, Milhazes N, et al. Simple coumarins and analogues in medicinal chemistry: occurrence, synthesis and biological activity. Curr Med Chem 2005;12:887-916 (Pubitemid 40443846)
4. Fylaktakidou KC, Hadjipavlou-Litina D, Litinas KE, Nicolaides DN. Natural and synthetic coumarin derivatives with antiinflammatory/antioxidant Activities. Curr Pharm Des 2004;10:3813-33 The antioxidant and anti-inflammatory properties of natural and synthetic coumarins are given and the structural requirements correlated with these activities are discussed. (Pubitemid 39409872)
5. He C, Zhang W, Xu X, et al. inventors, The Second Military Medical University, The Chinese People's Liberation Army, Peop. Rep. China, assignee. Application of coumarin compounds in preparing medicine for inducing directional differentiation of neural stem cell. WO040153; 2008
6. Zhang SY, Meng L, Gao WY, et al. Advances in biological activities of coumarins. Chin J Chin Mater Med 2005;30:410-14
7. Kubo H, Nagahori H, Tomigahara Y, et al. inventors, Sumitomo Chemical Co. Ltd Japan, assignee. Coumarin compound and use thereof. WO031706; 2009
8. Luu-The V, Zhang Y, Poirier D, Labrie F. Characteristics of human types 1, 2 and 3 17beta-hydroxysteroid dehydrogenase activities: oxidation/reduction and inhibition. J Steroid Biochem Mol Biol 1995;55:581-7 (Pubitemid 26019342)
9. Smith HJ, Nicholls PJ, Simons C, Le Lain R. Inhibitors of steroidogenesis as agents for the treatment of hormone-dependent cancers. Exp Opin Ther Patents 2001;11:789-824 This publication presents an extended study on 17β-HSD inhibitors.
10. Le Lain R, Barrell KJ, Saeed GS, et al. Some coumarins and triphenylethene derivatives as inhibitors of human testes microsomal 17beta-hydroxysteroid dehydrogenase (17beta-HSD type 3): further studies with tamoxifen on the rat testes microsomal enzyme. J Enzyme Inhib Med Chem 2002;17:93-100 (Pubitemid 34855326)
11. Borsche W, Lewinsohn M. Constituents of kawa root XIV. Cinnamoylacetic esters. Berichte 1933;66B:1792-801
12. Sova M, Perdih A, Kotnik M, et al. Flavonoids and cinnamic acid esters as inhibitors of fungal 17beta-hydroxysteroid dehydrogenase: a synthesis, QSAR and modelling study. Bioorg Med Chem 2006;14:7404-18 (Pubitemid 44486808)
13. Kubo H, Nagahori H, Tomigahara Y, et al. inventors, Sumitomo Chemical Co., Ltd., Japan, assignee. Coumarin compound and use thereof. WO031709; 2009
14. Parmar VS, Raj HG, Prasad AK, Jain SC. inventors, Delhi University, India and Vallabhbhai Patel Chest Institute, assignees. Coumarin compounds for the treatment of cardiovascular diseases and process for preparing the same. WO157020; 2009
15. Heidelbaugh TM, Cappiello JR, Nguyen P, Gomez DG. inventors, Allergan, Inc. USA, assignee. Coumarin compounds as receptors modulators with therapeutic utility. WO050054; 2011
16. Hale JJ, Neway W, Mills SG, et al. Potent S1P receptor agonists replicate the pharmacologic actions of the novel immune modulator FTY720. Bioorg Med Chem Lett 2004;14:3351-5 (Pubitemid 38624622)
17. Calvet JP, Blagg BSJ, Sundar SV, Magenheimer BS. inventors, University of Kansas, USA, assignees. Novobiocin analogues and treatment of polycystic kidney disease. US0082098; 2011
18. Yu XM, Shen G, Blagg BSJ. Synthesis of (-)-Noviose from 2,3-O-Isopropylidene-D-erythronolactol. J Org Chem 2004;69:7375-8 (Pubitemid 39363045)
19. Madhavan GR, Balraju V, Mallesham B, et al. Novel coumarin derivatives of heterocyclic compounds as lipid-lowering agents. Bioorg Med Chem Lett 2003;13:2547-51 (Pubitemid 36830770)
20. Shen G, Yu XM, Blagg BSJ. Syntheses of photolabile novobiocin analogues. Bioorg Med Chem Lett 2004;14:5903-6 (Pubitemid 39421541)
21. Yu XM, Shen G, Neckers L, et al. Hsp90 inhibitors identified from a library of novobiocin analogues. J Am Chem Soc 2005;127:12778-9 (Pubitemid 41339147)
22. Yamaguchi T, Hempson SJ, Reif GA, et al. Calcium restores a normal proliferation phenotype in human polycystic kidney disease epithelial cells. J Am Soc Nephrol 2006;17:178-87
23. Rao JM, Bhimapaka CR, Pullela VS, et al. inventors, Council of Scientific and Industrial Research New Delhi, India, assignee. Pharmaceutical composition useful as acetylcholinesterase inhibitors. US0009544; 2008
24. Piazzi L, Rampa A, Bisi A, et al. 3-(4-{[Benzyl(methyl)amino]methyl} phenyl)-6,7-dimethoxy-2H-2-chromenone (AP2238) inhibits both Acetylcholinesterase and Acetylcholinesterase-induced beta-Amyloid aggregation: a dual function lead for Alzheimer's disease therapy. J Med Chem 2003;46:2279-82 (Pubitemid 36637912)
25. Ellman GL, Courtney KD, Andres V Jr, Featherstone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961;7:88-95
26. Orlow SJ, Komatsu LN. inventors, New York University, USA, assignee. Compounds, compositions and methods for preventing skin darkening. US0190229; 2011
27. Orlow SJ. The biogenesis of melanosomes. In: The pigmentary system: Physiology and Pathophysiology. Nordlund JJ, Boissy RE, Hearing VJ, et al. editors. Oxford University Press; New York: 1998 A detailed presentation on the role and the physiology of the pigmentary system is given.
28. Liu G, Xue H, Ma T, et al. inventors, Institute of Materia Medica, Chinese Academy of Medical Sciences, Peop. Rep. China, assignee. Tetriacyclodipyranyl coumarins and the anti-HIV and antituberculosis uses thereof. EP2216335; 2010
29. Donglei Y, Madoka S, Lan X, et al. Recent progress in the development of coumarin derivatives as potent anti-HIV agents. Med Res Rev 2003;23:322-45 The review is presenting coumarins as promising molecular scaffolds for the development of HIV chemotherapeutic agents.
30. Kashman Y, Gustafson KR, Fuller RW, et al. The Calanolides, a Novel HIV-inhibitory class of coumarin derivatives from the tropical rainforest tree, calophyllum lanigerum. J Med Chem 1992;35:2735-43 Calanolide A the most active compound against HIV-1 replication.
31. Xue H, Lu X, Zheng P, et al. Highly Suppressing Wild-Type HIV-1 and Y181C Mutant HIV-1 Strains by 10-Chloromethyl-11-demethyl-12-oxocalanolide A with druggable profile. J Med Chem 2010;53:1397-401
32. Ma T, Liu L, Xue H, et al. Chemical library and structure-activity relationships of 11-Demethyl-12-oxo Calanolide A analogues as Anti-HIV-1 Agents. J Med Chem 2008;51:1432-46 (Pubitemid 351484798)
33. Galinis DL, Fuller RW, McKee TC, et al. Structure-Activity Modifications of the HIV-1 Inhibitors (+)-Calanolide A and (-)-Calanolide B1. J Med Chem 1996;39:4507-10 (Pubitemid 26359408)
34. Flavin MT, Rizzo JD, Khilevich A, et al. Synthesis, chromatographic resolution, and anti-human immunodeficiency virus activity of (±)-Calanolide A and its enantiomers. J Med Chem 1996;39:1303-13 (Pubitemid 26089845)
35. Xu ZQ, Barrow WW, Suling WJ, et al. Anti-HIV natural product (+)-calanolide A is active against both drug-susceptible and drug-resistant strains of Mycobacterium tuberculosis. Bioorg Med Chem 2004;12:1199-207 (Pubitemid 38251310)
36. Chen ZW, Zhou P, Ho DD, et al. Genetically divergent strains of simian immunodeficiency virus use CCR5 as a coreceptor for entry. J Virol 1997;4:2705-14 (Pubitemid 27119907)
37. Beckwith J, Dutton R, Boyd D, Berkmen M. inventors, President and Fellows of Harvard College, USA, assignee. Antimicrobial agents that target bacterial vitamin K epoxide reductase. WO045381; 2010
38. Dutton RJ, Wayman A, Wei JR, et al. Inhibition of bacterial disulfide bond formation by the anticoagulant warfarin. Proc Natl Acad Sci 2010;107:297-301
39. Goodstadt L, Ponting CP. Vitamin K epoxide reductase: homology, active site and catalytic mechanism. Trends Biochem Sci 2004;29:289-92 (Pubitemid 38968759)
40. Abdelhafez OM, Amin KM, Batran RZ, et al. Synthesis, anticoagulant and PIVKA-II induced by new 4-hydroxycoumarin derivatives. Bioorg Med Chem 2010;18:3371-8
41. Appendino G, Mercalli E, Fuzzati N, et al. Antimycobacterial Coumarins from the Sardinian Giant Fennel (Ferula communis). J Nat Prod 2004;67:2108-10 (Pubitemid 40092568)
42. Monti M, Pinotti M, Appendino G, et al. Characterization of anti-coagulant properties of prenylated coumarin ferulenol. Biochim Biophys Acta 2007;1770:1437-40
43. Ansell J, Bargqvist D. Current options in the prevention of thromboembolic disease. Drugs 2004;64:1-5 (Pubitemid 39280364)
44. Kulkarni MV, Kulkarni GM, Lin CH, Sun CM. Recent advances in coumarins and 1-azacoumarins as versatile biodynamic agents. Curr Med Chem 2006;13:2795-818 The authors describe coumarin derivatives with chemical modifications at different positions of the core structure that present antitumor activity. (Pubitemid 44509726)
45. Iikura H, Hyoudoh I, Aoki T, et al. inventors, Chugai Seiyaku Kabushiki Kaisha, Japan, assignee. Novel coumarin derivatives having antitumor activity. EP1982982; 2008
46. Sakasai M, Shibuya Y, Nagasawa A. inventors, Kao Corp. Chuo-ku Tokyo, Japan, assignee. NFAT Signal Inhibitor and Hair growing agent. EP2348025A1; 2011
47. Hsieh H-P, Chang J-Y, Kuo C-C, Chao Y-S. inventors, National Health Research Institutes, Taiwan, assignee. Coumarin Compounds and their use for treating cancer. US0312317; 2009
48. Kuo CC, Hsieh HP, Pan WY, et al. BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo. Cancer Res 2004;64:4621-8
49. ter Haar E, Kowalski RJ, Hamel E, et al. Discodermolide, a cytotoxic marine agent that stabilizes microtubules more potently than taxol. Biochemistry 1996;9:243-50 (Pubitemid 26037301)
50. Smith AB, Shaw SJ, Myles DC. inventors, The Trustees of the University of Pennsylvania & Kosan Biosciences, Inc., assignees. Discodermolide analogues and methods of their use. WO006184; 2009
51. Su G. inventor, Nanjing Zhongrui Pharmaceutical Co., Ltd., Peop. Rep. China, assignee. Coumarin derivatives, preparation processes and used there of. WO036656; 2009
52. Marquez N, Sancho R, Ballero M, et al. Imperatorin inhibits T-cell proliferation by targeting the transcription factor NFAT. Planta Medica 2004;70:1016-21 (Pubitemid 39587033)
53. Sakasai M, Shibuya Y, Nagasawa A. Kao Corp., Tokyo, Japan, NFAT signal inhibitor and Hair-growing agent. WO2010047103A1 2010
54. Kawasaki C, Okuyama T, Shibata S, Iitaka Y. Studies on coumarins of a Chinese drug "Qian Hu"; VI. Coumarins of Angelica edulis. Planta Medica 1984;50:492-6 (Pubitemid 15180172)
55. Lee K, Min JH, Lee K, et al. inventors, Korea Research Institute of Bioscience and Biotechnology, assignee. Novel Coumarin-based compounds, preparation method thereof and multidrug resistance inhibitory pharmaceutical compositions containing same as active ingredients. WO064817; 2010
56. Selkoe DJ. The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease. Trends Cell Biol 1998;8:447-53
57. Brown MS, Ye J, Rawson RB, Goldstein JL. Regulated intramembrane proteolysis: a control mechanism conserved from bacteria to humans. Cell 2000;18:391-8
58. Zhu L, Djaballah H, Li Y, Shelton CC. inventors, Sloan-Kettering Institute for Cancer Research, New York, USA, assignee. Coumarin-based compounds. WO075280; 2010